XML 64 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
Net Income (Loss) Per Share
 12 Months Ended
Dec. 31, 2014
Net Income (Loss) Per Share [Abstract]  
Net Income (Loss) Per Share
13. Net Income (Loss) Per Share

Our basic net income (loss) per share amounts have been computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. For 2014, we reported net income, and the computation of diluted earnings per share is based upon the weighted-average number of our common shares and dilutive effect, determined using the treasury stock method, of potential common shares outstanding including amount of unrecognized compensation expense. In periods where shares to be issued upon the assumed conversion of the contingent consideration liability have an anti-dilutive effect on the calculation of diluted earnings per share, these shares are excluded from the calculation. For 2013 and 2012, we reported net losses and, therefore, potential common shares were not included since such inclusion would have been anti-dilutive. As of December 31, 2012 our 28 shares of unvested restricted stock with non-forfeitable rights to dividends were outstanding; all such shares were vested at the end of December 31, 2013. The allocation of 2012 net losses to these participating securities pursuant to the two-class method is not material to both basic and diluted earnings per share. The calculations of net loss per share, basic and diluted, are as follows:

  
Net Income (Loss)
 (Numerator)
  
Weighted Average
Common Shares
 (Denominator)
  
Per Share
 Amount
 
2014:
      
Basic
 
$
4,410
   
68,185
  
$
0.06
 
  Dilutive effect of contingent consideration liability
  
-
   
-
     
  Dilutive effect of stock options
  
-
   
58
     
Diluted
 
$
4,410
   
68,243
  
$
0.06
 
2013:
            
Basic and diluted
 
$
(42,572
)
  
55,798
  
$
(0.76
)
2012:
            
Basic and diluted
 
$
(35,431
)
  
34,754
  
$
(1.02
)


PROGENICS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - continued
(amounts in thousands, except per share amounts or as otherwise noted)
 
During 2014, 2013 and 2012, anti-dilutive common shares excluded from diluted per share amounts consist of the following:

  
2014
  
2013
  
2012
  
Weighted
Average
 Number
 
Weighted
Average
 Exercise Price
  
Weighted
Average
 Number
  
Weighted
Average
 Exercise Price
  
Weighted
Average
 Number
  
Weighted
Average
 Exercise Price
Options
  
5,036
 
$
10.56
   
5,969
  
$
11.54
   
5,947
  
$
12.32
Contingent consideration liability
  
3,457
      
3,544
       
-
    
Restricted stock
  
-
      
-
       
60
    
Total
  
8,493
      
9,513
       
6,007